{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:22:39Z","timestamp":1740108159051,"version":"3.37.3"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T00:00:00Z","timestamp":1652054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"DOI":"10.1007\/s00108-022-01349-1","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T13:04:42Z","timestamp":1652101482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beinvenenthrombose und Lungenembolie","Deep vein thrombosis and pulmonary embolism"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6192-1741","authenticated-orcid":false,"given":"Rupert","family":"Bauersachs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"1349_CR1","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli\u00a0G, Becattini\u00a0C, Meyer\u00a0G et\u00a0al (2020) Apixaban for the treatment of venous thromboembolism associated with cancer. N\u00a0Engl J Med 382:1599\u20131607","journal-title":"N Engl J Med"},{"key":"1349_CR2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2012","unstructured":"Agnelli\u00a0G, Buller\u00a0HR, Cohen\u00a0A et\u00a0al (2012) Apixaban for extended treatment of venous thromboembolism. N\u00a0Engl J Med 368:699\u2013708","journal-title":"N Engl J Med"},{"key":"1349_CR3","first-page":"1","volume-title":"Angio Update: Handbuch Gef\u00e4ssmedizin 2020","author":"R Bauersachs","year":"2020","unstructured":"Bauersachs\u00a0R (2020) Akuttherapie und Prolongierte Sekund\u00e4rpr\u00e4vention Ven\u00f6ser Thromboembolien. In: Lindhoff-Last\u00a0E, Debus\u00a0ES, Kellersmann\u00a0R, Tepe\u00a0G (Hrsg) Angio Update: Handbuch Gef\u00e4ssmedizin 2020. med publico, Wiesbaden, S 1\u201335"},{"key":"1349_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1055\/s-0040-1701476","volume":"40","author":"RM Bauersachs","year":"2020","unstructured":"Bauersachs\u00a0RM, Herold\u00a0J (2020) Oral anticoagulation in the elderly and frail. Hamostaseologie 40:74\u201383","journal-title":"Hamostaseologie"},{"key":"1349_CR5","first-page":"CD002783","volume":"1","author":"C Broderick","year":"2021","unstructured":"Broderick\u00a0C, Watson\u00a0L, Armon\u00a0MP (2021) Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb. Cochrane Database Syst Rev 1:CD2783","journal-title":"Cochrane Database Syst Rev"},{"key":"1349_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.thromres.2020.12.031","volume":"199","author":"MA De Winter","year":"2021","unstructured":"De Winter\u00a0MA, Van Es\u00a0N, Buller\u00a0HR et\u00a0al (2021) Prediction models for recurrence and bleeding in patients with venous thromboembolism: A systematic review and critical appraisal. Thromb Res 199:85\u201396","journal-title":"Thromb Res"},{"key":"1349_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejim.2021.01.021","volume":"86","author":"M Ebner","year":"2021","unstructured":"Ebner\u00a0M, Pagel\u00a0CF, Sentler\u00a0C et al (2021) Venous lactate improves the prediction of in-hospital adverse outcomes in normotensive pulmonary embolism. Eur J Intern Med 86:25\u201331","journal-title":"Eur J Intern Med"},{"key":"1349_CR8","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/ehjacc\/zuab038","volume":"10","author":"M Ebner","year":"2021","unstructured":"Ebner\u00a0M, Sentler\u00a0C, Harjola\u00a0VP et al (2021) Outcome of patients with different clinical presentations of high-risk pulmonary embolism. Eur Heart J Acute Cardiovasc Care 10:787\u2013796","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"1349_CR9","first-page":"61875","volume":"6736","author":"T Enden","year":"2012","unstructured":"Enden\u00a0T, Klow\u00a0NE, Slagsvold\u00a0CE et al (2012) Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis the CaVenT study: a\u00a0randomised controlled trial. Lancet 6736:61875\u201361878","journal-title":"Lancet"},{"key":"1349_CR10","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.thromres.2021.05.007","volume":"203","author":"S Goto","year":"2021","unstructured":"Goto\u00a0S, Turpie\u00a0AGG, Farjat\u00a0AE et al (2021) The influence of anemia on clinical outcomes in venous thromboembolism: Results from GARFIELD-VTE. Thromb Res 203:155\u2013162","journal-title":"Thromb Res"},{"key":"1349_CR11","first-page":"3","volume":"39","author":"V Hach-Wunderle","year":"2010","unstructured":"Hach-Wunderle\u00a0V et al (2010) Interdisziplin\u00e4re S2: Leitlinie: Diagnostik und Therapie der Bein- und Beckenvenenthrombose und der Lungenembolie. VASA 39:3\u201324","journal-title":"VASA"},{"key":"1349_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0741-5214(12)02497-4","volume":"57","author":"V Hach-Wunderle","year":"2013","unstructured":"Hach-Wunderle\u00a0V, Bauersachs\u00a0R, Gerlach\u00a0HE et al (2013) Postthrombotic syndrome three years after deep venous thrombosis in the TULIPA PLUS registry. J\u00a0Vasc Surg 57:5\u201312","journal-title":"J Vasc Surg"},{"key":"1349_CR13","first-page":"1","volume":"45","author":"V Hach-Wunderle","year":"2016","unstructured":"Hach-Wunderle\u00a0V, Gerlach\u00a0H, Konstantinides\u00a0S et al (2016) Interdisziplin\u00e4re S2k: Leitlinie: Diagnostik und Therapie der Bein- und Beckenvenenthrombose und der Lungenembolie; Registernummer 065 - 002. VASA 45:1\u201348","journal-title":"VASA"},{"key":"1349_CR14","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1111\/jth.15426","volume":"19","author":"J Herold","year":"2021","unstructured":"Herold\u00a0J, Bauersachs\u00a0R (2021) Comment on: Reduced dose direct oral anticoagulants (DOACs) in the extended treatment of venous thromboembolism: a\u00a0systematic review and meta-analysis. Journal of Thrombosis and Haemostasis: JTH 2018 Jul; 16(7): 1288\u201395. J\u00a0Thromb Haemost 19:2357\u20132358","journal-title":"J Thromb Haemost"},{"key":"1349_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61902-9","author":"SR Kahn","year":"2013","unstructured":"Kahn\u00a0SR, Shapiro\u00a0S, Wells\u00a0PS, Rodger\u00a0MA, Kovacs\u00a0MJ, Anderson\u00a0DR, Tagalakis\u00a0V, Houweling\u00a0AH, Ducruet\u00a0T, Holcroft\u00a0C, Johri\u00a0M, Solymoss\u00a0S, Miron\u00a0MJ, Yeo\u00a0E, Smith\u00a0R, Schulman\u00a0S, Kassis\u00a0J, Kearon\u00a0C, Chagnon\u00a0I, Wong\u00a0T, Demers\u00a0C, Hanmiah\u00a0R, Kaatz\u00a0S, Selby\u00a0R, Rathbun\u00a0S, Desmarais\u00a0S, Opatrny\u00a0L, Ortel\u00a0TL, Ginsberg\u00a0JS (2013) Compression stockings to prevent post-thrombotic syndrome: a\u00a0randomised placebo-controlled trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(13)61902-9","journal-title":"Lancet"},{"key":"1349_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.7326\/0003-4819-149-10-200811180-00004","volume":"149","author":"SR Kahn","year":"2008","unstructured":"Kahn\u00a0SR, Shrier\u00a0I, Julian\u00a0JA et\u00a0al (2008) Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 149:698\u2013707","journal-title":"Ann Intern Med"},{"key":"1349_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejvs.2020.09.023","volume":"61","author":"SK Kakkos","year":"2021","unstructured":"Kakkos\u00a0SK, Gohel\u00a0M, Baekgaard\u00a0N et\u00a0al (2021) Editor\u2019s choice\u2014European Society for Vascular Surgery (ESVS) 2021 clinical practice guidelines on the management of venous thrombosis. Eur J Vasc Endovasc Surg 61:9\u201382","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"1349_CR18","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/jth.13336","volume":"14","author":"C Kearon","year":"2016","unstructured":"Kearon\u00a0C, Ageno\u00a0W, Cannegieter\u00a0SC et\u00a0al (2016) Categorization of patients as having provoked or unprovoked venous thromboembolism: Guidance from the SSC of ISTH. J\u00a0Thromb Haemost 14:1480\u20131483","journal-title":"J Thromb Haemost"},{"key":"1349_CR19","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2018-99-113589","volume":"132","author":"F Khan","year":"2018","unstructured":"Khan\u00a0F, Rahman\u00a0A, Carrier\u00a0M et al (2018) Meta-analysis of long-term risk of recurrent venous thromboembolism after stopping anticoagulation in men and women with first unprovoked venous thromboembolism. Blood 132:2527\u20132527","journal-title":"Blood"},{"key":"1349_CR20","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.7326\/M21-1094","volume":"174","author":"F Khan","year":"2021","unstructured":"Khan\u00a0F, Tritschler\u00a0T, Kimpton\u00a0M et al (2021) Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis. Ann Intern Med 174:1420\u20131429","journal-title":"Ann Intern Med"},{"key":"1349_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides\u00a0SV, Meyer\u00a0G, Becattini\u00a0C et\u00a0al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart\u00a0J 41:543\u2013603","journal-title":"Eur Heart J"},{"key":"1349_CR22","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman\u00a0GH, Carrier\u00a0M, Ay\u00a0C et\u00a0al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5:927\u2013974","journal-title":"Blood Adv"},{"key":"1349_CR23","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/jth.15358","volume":"19","author":"KA Martin","year":"2021","unstructured":"Martin\u00a0KA, Beyer-Westendorf\u00a0J, Davidson\u00a0BL et al (2021) Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC subcommittee on control of anticoagulation. J\u00a0Thromb Haemost 19:1874\u20131882","journal-title":"J Thromb Haemost"},{"key":"1349_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwab088","author":"L Mazzolai","year":"2021","unstructured":"Mazzolai\u00a0L, Ageno\u00a0W, Alatri\u00a0A, Bauersachs\u00a0R, Becattini\u00a0C, Brodmann\u00a0M, Emmerich\u00a0J, Konstantinides\u00a0S, Meyer\u00a0G, Middeldorp\u00a0S, Monreal\u00a0M, Righini\u00a0M, Aboyans\u00a0V (2021) Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. Eur J Prev Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwab088","journal-title":"Eur J Prev Cardiol"},{"key":"1349_CR25","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1016\/S2352-3026(19)30209-1","volume":"7","author":"P Notten","year":"2020","unstructured":"Notten\u00a0P, Ten Cate-Hoek\u00a0AJ, Arnoldussen\u00a0C et al (2020) Ultrasound-accelerated catheter-directed thrombolysis versus anticoagulation for the prevention of post-thrombotic syndrome (CAVA): a\u00a0single-blind, multicentre, randomised trial. Lancet Haematol 7:e40\u2013e49","journal-title":"Lancet Haematol"},{"key":"1349_CR26","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/rth2.12330","volume":"4","author":"P Notten","year":"2020","unstructured":"Notten\u00a0P, Van Laanen\u00a0JHH, Eijgenraam\u00a0P et al (2020) Quality of anticoagulant therapy and the incidence of in-stent thrombosis after venous stenting. Res Pract Thromb Haemost 4:594\u2013603","journal-title":"Res Pract Thromb Haemost"},{"key":"1349_CR27","volume-title":"Obesity update 2017","author":"OECD","year":"2018","unstructured":"OECD (2018) Obesity update 2017"},{"key":"1349_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.5482\/ha-1147","volume":"31","author":"I Pabinger","year":"2011","unstructured":"Pabinger\u00a0I, Alt-Epping\u00a0B, Demarmels Biasutti\u00a0F et al (2011) Venous thrombembolism in tumour patients. Hamostaseologie 31:281\u2013290 (quiz 291\u2013282)","journal-title":"Hamostaseologie"},{"key":"1349_CR29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711948","author":"GE Raskob","year":"2017","unstructured":"Raskob\u00a0GE, van Es\u00a0N, Verhamme\u00a0P, Carrier\u00a0M, Di Nisio\u00a0M, Garcia\u00a0D, Grosso\u00a0MA, Kakkar\u00a0AK, Kovacs\u00a0MJ, Mercuri\u00a0MF, Meyer\u00a0G, Segers\u00a0A, Shi\u00a0M, Wang\u00a0TF, Yeo\u00a0E, Zhang\u00a0G, Zwicker\u00a0JI, Weitz\u00a0JI, Buller\u00a0HR (2017) Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1711948","journal-title":"N Engl J Med"},{"key":"1349_CR30","first-page":"1","volume":"2020","author":"H Riess","year":"2020","unstructured":"Riess\u00a0H, Angelillo-Scherrer\u00a0A, Alt-Epping\u00a0B et al (2020) Onkopedia-Leitlinie Ven\u00f6se Thrombembolien (VTE) bei Tumorpatienten. DGHO 2020:1\u201329","journal-title":"DGHO"},{"key":"1349_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.thromres.2021.03.012","volume":"202","author":"L Skeith","year":"2021","unstructured":"Skeith\u00a0L, Le Gal\u00a0G, Rodger\u00a0MA (2021) Oral contraceptives and hormone replacement therapy: How strong a\u00a0risk factor for venous thromboembolism? Thromb Res 202:134\u2013138","journal-title":"Thromb Res"},{"key":"1349_CR32","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens\u00a0SM, Woller\u00a0SC, Baumann Kreuziger\u00a0L et\u00a0al (2021) Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160:e545\u2013e608","journal-title":"Chest"},{"key":"1349_CR33","volume-title":"Hormonal contraception. Guideline of the German Society of Gynecology and Obstetrics (S3-Level, AWMF Registry No. 015\/015, December 2018). Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u202fV. (AWMF)","author":"P Stute","year":"2019","unstructured":"Stute\u00a0P, Kiesel\u00a0L, Bauersachs\u00a0R et al (2019) Hormonal contraception. Guideline of the German Society of Gynecology and Obstetrics (S3-Level, AWMF Registry No. 015\/015, December 2018). Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u202fV. (AWMF)"},{"key":"1349_CR34","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/S2352-3026(17)30227-2","volume":"5","author":"AJ Ten Cate-Hoek","year":"2018","unstructured":"Ten Cate-Hoek\u00a0AJ, Amin\u00a0EE, Bouman\u00a0AC et al (2018) Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a\u00a0multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. Lancet Haematol 5:e25\u2013e33","journal-title":"Lancet Haematol"},{"key":"1349_CR35","doi-asserted-by":"publisher","first-page":"e005265","DOI":"10.1136\/bmjopen-2014-005265","volume":"4","author":"AJ Ten Cate-Hoek","year":"2014","unstructured":"Ten Cate-Hoek\u00a0AJ, Bouman\u00a0AC, Joore\u00a0MA et al (2014) The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a\u00a0randomised controlled trial. BMJ Open 4:e5265","journal-title":"BMJ Open"},{"key":"1349_CR36","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1111\/jth.15427","volume":"19","author":"L Vasanthamohan","year":"2021","unstructured":"Vasanthamohan\u00a0L, Boonyawat\u00a0K, Chai-Adisaksopha\u00a0C et al (2021) Reduced-dose direct oral anticoagulants (DOACs) in the extended treatment of venous thromboembolism: A systematic review and meta-analysis-Response to commentary. J\u00a0Thromb Haemost 19:2359\u20132360","journal-title":"J Thromb Haemost"},{"key":"1349_CR37","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1056\/NEJMoa1615066","volume":"377","author":"S Vedantham","year":"2017","unstructured":"Vedantham\u00a0S, Goldhaber\u00a0SZ, Julian\u00a0JA et al (2017) Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N\u00a0Engl J Med 377:2240\u20132252","journal-title":"N Engl J Med"},{"key":"1349_CR38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ahj.2013.01.024","volume":"165","author":"S Vedantham","year":"2013","unstructured":"Vedantham\u00a0S, Goldhaber\u00a0SZ, Kahn\u00a0SR et al (2013) Rationale and design of the ATTRACT Study: a\u00a0multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis. Am Heart\u00a0J 165:523\u2013530.e3","journal-title":"Am Heart J"},{"key":"1349_CR39","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","volume":"376","author":"JI Weitz","year":"2017","unstructured":"Weitz\u00a0JI, Lensing\u00a0AW, Prins\u00a0MH et\u00a0al (2017) Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N\u00a0Engl J Med 376:1211\u20131222","journal-title":"N Engl J Med"},{"key":"1349_CR40","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young\u00a0AM, Marshall\u00a0A, Thirlwall\u00a0J et al (2018) Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a\u00a0randomized trial (SELECT-D). J\u00a0Clin Oncol 36:2017\u20132023","journal-title":"J Clin Oncol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01349-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01349-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01349-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T13:04:52Z","timestamp":1652101492000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01349-1"}},"subtitle":["Diagnostik und Therapie","Diagnosis and treatment"],"short-title":[],"issued":{"date-parts":[[2022,5,9]]},"references-count":40,"alternative-id":["1349"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01349-1","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"type":"print","value":"0020-9554"},{"type":"electronic","value":"1432-1289"}],"subject":[],"published":{"date-parts":[[2022,5,9]]},"assertion":[{"value":"28 April 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Bauersachs gibt an, dass er sich bei der Erstellung des Beitrages nicht von wirtschaftlichen Interessen leiten lie\u00df. Er legt folgende potenzielle Interessenkonflikte offen: Forschungsunterst\u00fctzung: Bayer, Viatris, Bay. StMGP. Vortrags- und Beratert\u00e4tigkeit: Bayer, Bristol-Myers Squibb GmbH & Co. KGaA, LEO-Pharma, Pfizer, Viatris.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}